TG Therapeutics TGTX Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
- TG Therapeutics (TGTX) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $72.22M in Q1 2026.
- How has TG Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
- TG Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) decreased by 49.9% year-over-year, from $144.1M to $72.22M.
- What is the long-term trend for TG Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
- Over 5 years (2020 to 2025), TG Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) has grown at a 3.9% compound annual growth rate (CAGR), from $51.99M to $62.82M.